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Objective:
Although highly active antiretroviral therapy (HAART) resolves a significant proportion
of anemia among HIV-patients in Western cohorts, outcomes may vary in developing
countries, due to a higher prevalence of nutritional deficiencies, intestinal parasites,
tuberculosis, and opportunistic infections. The purpose of this study is to describe the
prevalence of, factors associated with, and influence of HAART on, anemia among HIV-
infected individuals in South India.
Methods:
To examine factors associated with anemia, the first-recorded hemoglobin values for
adults who visited an HIV tertiary care center in Chennai, India between January 1996
and April 2006 were collected (n=7069). Univariate and multivariate regression analyses
were performed to examine associations between anemia and stage of HIV disease, co-
morbidities, and medications. To examine the influence of HAART use on anemia on a
smaller subset of patients (n=401), the mean of baseline hemoglobin values measured
within 3 months prior to HAART initiation was compared to the mean of follow-up
hemoglobin values collected between 3-12 months after HAART initiation. A similar
analysis based on the time of AIDS onset was performed for a control group of patients
with clinical/immunological AIDS who never received HAART (n=77).
Results:
The prevalence of anemia in the overall cohort was 40% by the WHO definition. While
22% of patients with CD4 counts >500 cells/L had anemia, this increased to 60% for
those with CD4 counts <100 cells/L (p<0.001). In multivariate analysis, CD4 count
<100 cells/L, underweight body mass index, female sex, active tuberculosis, and lack of
cotrimoxazole prophylaxis had significant associations with anemia. In the analysis of
the influence of HAART on anemia, median baseline CD4 count and mean time to
follow-up hemoglobin value were similar for both the HAART and control arms. For
patients who initiated HAART, the mean baseline hemoglobin of 10.7g/dL significantly
increased to 12.4g/dL during the year of follow-up (p<0.001). While 46.6% of patients
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were not anemic at HAART initiation, this increased significantly to 78.1% during
follow-up (p<0.001). Severe grades 3 and 4 anemia decreased from 12.5% to 2% for
those on HAART (p<0.001). For the control arm of patients who never received
HAART, the increase in mean baseline hemoglobin from 10.50 to 11.10g/dL did not
reach significance (p=0.06). While the percent of non-anemic patients increased from
40.3 to 54.5% on follow-up in this group, this was not significant (p=0.291).
Conclusion:
Anemia is strongly correlated with the severity of immunosuppression in this population
seen at an HIV tertiary referral center. Endemic malnutrition and tuberculosis further
exacerbate the level of anemia. Anemia resolved in a large proportion of patients within
the first year of HAART use. Therefore, antiretroviral therapy, nutritional
supplementation, and aggressive tuberculosis treatment should be the cornerstones of
anemia management in this setting. The high prevalence of anemia among patients with
immunological AIDS complicates the roll-out of antiretroviral regimens containing
zidovudine, a drug which may exacerbate anemia, and highlights the need for increased
access to alternative nucleoside reverse transcriptase inhibitors in developing countries.
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INTRODUCTION
Anemia is widespread in the general population of developing countries, especially
among women.(1) In India, more than half of women are estimated to be anemic, and
nearly one-fifth suffer from moderate or severe levels of anemia.(2) It is also one of the
most frequent morbidities and the most common hematological complication associated
with HIV infection, with rates increasing as the disease progresses.(3-5) Anemia has
been shown to influence the natural history of HIV disease by accelerating the rate of
disease progression and increasing mortality in both developed and developing country
studies.(4, 6, 7) Conversely, survival time in HIV-infected individuals may be improved
with recovery from anemia.(4) By causing symptoms of fatigue and exhaustion, anemia
also has a major impact on the quality of life of people living with HIV (8, 9) and
possibly even exacerbates poverty in communities with a high HIV prevalence.(10)
The pathogenesis of anemia in HIV-infected individuals is complex. While much of the
burden is attributable to the anemia of chronic disease, nutritional deficiencies,
opportunistic infections, malignancies, parvovirus B19, viral inhibition of hematopoetic
stem cells, and medications (including antiretroviral therapy) also contribute to anemia in
those with HIV disease.(11) In most cases, the etiology is multifactorial.(11, 12) In
cohort studies from developed countries, risk factors independently associated with
anemia in HIV-infected individuals included age, female gender, African-American race,
low CD4 cell count, and drugs like zidovudine, fluconazole, and ganciclovir.
Independently associated co-morbidities in these studies included Mycobacterium avium
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complex, lymphoma, bacterial pneumonia, septicemia, oral candidiasis, and other
hematological abnormalities (i.e., neutropenia and thrombocytopenia).(4, 7, 13)
When superimposed on already high levels of background anemia, HIV disease in
developing countries may produce extremely high rates of anemia. Compared to the 20-
60% percent prevalence of anemia found in U.S. and European cohorts of HIV
patients,(4, 7, 13, 14) multiple studies of HIV-infected individuals from sub-Saharan
Africa have found the prevalence of anemia ranges from 70-90%, though many of these
studies were done in pregnant women or patients co-infected with tuberculosis.(6, 11, 15-
17) Risk factors for anemia in these settings possibly vary from those in developed
countries due to high rates of endemic malnutrition, helminth infections, malaria, and a
different spectrum of HIV-associated opportunistic infections. For example, multiple
studies have suggested that tuberculosis (TB), which is the second most common
opportunistic infection in South India,(18) plays a major role in the etiology of anemia
among HIV-infected patients in developing countries.(15, 19)
Multiple studies from developed countries suggest that use of highly active antiretroviral
therapy (HAART) reduces the risk of anemia in patients with HIV infection and greatly
improves hemoglobin values in many patients who are already anemic at the time of
HAART initiation.(3, 7, 20-23) While these data from Western cohorts is promising, the
beneficial impact of HAART on anemia may be diminished in developing countries,
where nutritional deficiencies, intestinal parasites, malaria, tuberculosis, and the higher
burden of opportunistic infections may deplete marrow reserves, resulting in persistence
8
of anemia despite viral suppression and reconstitution of the immune system. Few
studies have examined HIV-associated anemia in developing countries, where the vast
majority of HIV-infected individuals live, and no study has examined the impact of
HAART on anemia in these settings. These questions are especially important in India,
the country that currently has the largest population of people living with HIV.(24) Here
we report the prevalence of, factors associated with, and impact of HAART on, anemia
among HIV-infected individuals at an HIV/AIDS tertiary care center in South India.
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STATEMENT OF PURPOSE AND HYPOTHESIS
This study has three purposes:
1. To report the prevalence of anemia in the patient population of the largest private HIV
tertiary care center in South India.
2. To determine clinical factors associated with anemia and the independent odds of
having anemia with each of these factors.
3. To examine the impact of highly active antiretroviral therapy on anemia in this patient
population.
For each of the purposes noted above, I suggest the following hypotheses:
1. Due to the impact of HIV disease, the prevalence of anemia in this clinic population
will be higher than that found in the general South Indian population. It will also be
higher than those found in most HIV-infected cohorts in Western countries (due to the
higher level of baseline anemia in the Indian population). The prevalence of anemia will
increase in patients with more advanced HIV disease, due to the higher burden of
infections and malnutrition in patients with more advanced immunosuppression.
2. Multiple clinical factors will be associated with anemia in this cohort, highlighting the
many etiologies of anemia in this patient population. While immunosuppression will be
associated with anemia, malnutrition and tuberculosis will be more strongly associated
with anemia in this cohort when compared to studies from developed countries.
3. There will be minimal or no resolution of anemia after HAART initiation in this
patient population because the high burden of non-HIV-associated etiologies of anemia




The Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE) is a non-
profit, non-governmental, HIV tertiary referral clinic in Chennai (formerly Madras),
India, which has provided a continuum of care—including voluntary counseling and
testing, outpatient, and inpatient services—to over 9000 patients since 1993 (Illustrations
1, 2, and 3). All patients are treated according to World Health Organization (WHO)
guidelines for resource-limited settings.(25) YRG CARE has a 20-bed inpatient ward
where patients are admitted for management of HIV-associated opportunistic infections
and toxicities from antiretroviral drugs. While diseases not associated with HIV (e.g.,
malaria) are usually managed in other hospitals, YRG CARE sometimes admits patients
for non-HIV related illnesses if they have been refused admission elsewhere due to their
HIV status. While the majority of patients cared for at the clinic are adults, the clinic also
holds a pediatric outpatient clinic every one to two months and manages children in the
inpatient ward throughout the year.
YRG CARE has played a vital role in shaping India’s response to the HIV epidemic. The
founder and director of the clinic, Dr. Suniti Solomon, led the team that discovered the
first cases of HIV in India in 1986. After managing HIV cases in Chennai’s large
government hospital, Dr. Solomon retired from government service to start the clinic in
the early 1990s. In addition to patient care, YRG CARE has directed the development of
sexual education programs throughout thousands of middle and high schools in the state
of Tamil Nadu. The clinic has research affiliations with several major U.S. medical
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schools, including Brown University and Johns Hopkins and is a research site for
multiple NIH-funded clinical trials.
YRG CARE was one of the first medical centers in India to offer antiretroviral therapy to
people living with HIV. While initially restricted to patients who could afford it, the
availability of antiretroviral therapy has been expanded in recent years through programs
funded by the United Nations Global Fund for AIDS, TB, and Malaria and AIDS Project
Los Angeles, which subsidize therapy for poor patients. Since the initiation of free roll-
out of antiretroviral therapy by the Indian government in late 2004, patients who cannot
afford antiretroviral therapy and are not covered by subsidy programs are referred to
government roll-out centers to receive therapy. Patients with access to therapy are
advised to initiate these medications at CD4 cell counts <200 cells/L or if there is a
history of an AIDS-defining illness. Patients are followed up every three months or as
clinically indicated. The majority of patients visiting the clinic come from the southern
Indian states of Tamil Nadu and Andhra Pradesh, where surveys estimate rates of
background anemia among women to be 57% and 50% respectively.(2)
Analysis was done using the previously validated YRG CARE HIV Observational
Database,(26) This database is updated after every patient visit by trained research
nurses who extract demographic and clinical details based on a standardized data
collection form approved by YRG CARE’s independent institutional review board. Data
collected include demographic variables (age, sex, mode of HIV transmission), clinical
assessments (new opportunistic infections and HIV-related co-morbidities), use of
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antiretroviral medications, adverse events from antiretroviral medications, use of
cotrimoxazole prophylaxis, and laboratory data (CD4 cell counts, hemoglobin values, and
plasma viral loads, if available). Data is not collected on use of complementary and
alternative medicines.
In this study, data from the YRG CARE HIV Observational database is used to do two
separate analyses. The first analysis uses cross-sectional data from a larger sample of
patients to examine the prevalence of, and risk-factors associated with, anemia in the
YRG CARE cohort. The second analysis uses a smaller sample of patients to examine the
impact of HAART on anemia. The methods for these two different analyses are described
below.
Prevalence of Anemia and Factors Associated with Anemia
For the first analysis, patients who visited YRG CARE between January 1, 1996 and
March 31, 2006, who were greater than 18 years of age at the time of enrollment for care
at the clinic, and who had at least one hemoglobin value in the database were included.
The analysis was performed using the first recorded hemoglobin value after the patient’s
enrollment for care at the clinic.
Anemia was classified by WHO criteria for both men and women: grade 0 or “non-
anemic” (hemoglobin values 11 g/dL), grade 1 or “mild” anemia (9.5-10.9 g/dL), grade
2 or “moderate” anemia (8-9.4 g/dL), grade 3 or “severe” anemia (6.5-7.9 g/dL), and
grade 4 or “life-threatening” anemia (<6.5 g/dL). For comparison with other studies,
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anemia was also reclassified as hemoglobin values <12 g/dL for women and <13 g/dL for
men as noted. Patients who had used triple drug antiretroviral therapy (ART) for at least
one month prior to the date of the hemoglobin value were considered to be “on highly
active antiretroviral therapy (HAART),” while those who used single or double drug
ART for at least one month prior to the date of the hemoglobin were considered to be “on
mono/dual therapy.” Patients who never started ART or took it for less than one month
prior to the hemoglobin value were considered to be “not on ART.” Of note, the HAART
regimen for nearly all patients at YRG CARE consists of stavudine or zidovudine +
lamivudine + nevirapine or efavirenz, with more patients using stavudine and nevirapine
over zidovudine and efavirenz, respectively, due to the lower cost of the former
medications. Less than one percent of patients are taking other antiretroviral medications
such as tenofovir, abacavir, or protease inhibitors. Patients who took cotrimoxazole
prophylaxis for at least seven days prior to the date of hemoglobin value were considered
to be “on cotrimoxazole.” Most patients are initiated on cotrimoxazole prophylaxis at
CD4 cell counts between 200-300 cells/L when possible; however, since many patients
initially only present for care when they have reached very advanced stages of
immunosuppression, some are initiated on prophylaxis at lower CD4 counts.
Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2),
and BMI values within one month prior to or after the date of the hemoglobin for a given
patient were included in the analysis. “Underweight” was defined as a BMI less than
18.5 kg/m2, “normal weight” as a BMI from 18.5 to 25 kg/m2, and “overweight/obese” as
a BMI of 25 kg/m2 or greater. “Gastroenteropathy” included all cases of chronic
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diarrhea, including confirmed diagnoses of cryptosporidium and Isospora belli infection.
“Renal disease” included all patients with chronic renal insufficiency, end stage renal
disease, and HIV nephropathy.
CD4 cell counts were included in the analysis if recorded in the two months prior to or
after the date of the hemoglobin. Patients were considered to have the following diseases
if any serological diagnosis was recorded prior to the date of the hemoglobin: hepatitis C
virus infection, hepatitis B virus infection, and syphilis. All other relevant HIV-
associated co-morbidities in the database were divided those considered to have chronic
presentations and those with acute presentations. Diseases with acute presentation were
included in the analysis if diagnosed within the one month prior to or after the date of the
hemoglobin. This group consisted of the following: oral candidiasis, esophageal
candidiasis, Pneumocystic jiroveci pneumonia (PCP), cryptococcal meningitis,
cytomegalovirus retinitis, oral hairy leukoplakia, herpes zoster, herpes simplex,
gastroenteropathy, bacterial pneumonia, bacterial meningitis, bacterial infections of the
skin, immune reconstitution syndrome, and immune thrombocytopenia. Diseases with
chronic presentation were included in the analysis if diagnosed within the two months
prior to or after the date of the hemoglobin for a given patient. This group consisted of
the following diseases: pulmonary TB, extrapulmonary TB, lymphadenopathy, ascites,
and renal disease. The association of anemia with Kaposi sarcoma is not reported, since
this neoplasm is very rare among HIV patients in India (likely due to the very low
prevalence of human herpes virus-8 in the population). Only two cases of Kaposi
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sarcoma from India have been reported in the medical literature, both among immigrants
to India.
Impact of HAART on Anemia
The second analysis included patients who visited YRG CARE between January 1, 1996
and March 31, 2006 and who were greater than 18 years of age at the time of enrollment
for care at the clinic. This sample was further restricted to patients who had been on
HAART for at least three months and had not interrupted therapy for greater than 14 days
within that time period. Further, all patients had to have a baseline hemoglobin value and
at least one follow-up hemoglobin value. A baseline hemoglobin value was defined as
any hemoglobin measured within the three months prior to, or within two days after, the
date of HAART initiation. A follow-up hemoglobin value was defined as any
hemoglobin value collected between the three to twelve months following the date of
HAART initiation.
This sample of patients on HAART was compared to a control group of patients who had
clinical or immunological AIDS but never received HAART. Almost all of these patients
suffered from AIDS prior to the widespread availability of HAART in India, and
therefore did not received HAART despite qualifying for the therapy on clinical or
immunological grounds. Immunological AIDS was defined as any CD4 cell count ≤200
cells/μL. Clinical AIDS was defined as having an AIDS-defining illness as defined by
WHO criteria. For these patients, a baseline hemoglobin value was defined as any
hemoglobin measured within the three months prior to, or within two days after, the date
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of diagnosis of clinical or immunological AIDS. A follow-up hemoglobin value was
defined as any hemoglobin value collected between the three to twelve months following
the date of diagnosis of clinical or immunological AIDS.
For both the HAART and control groups, baseline hemoglobin data was compared to the
mean of all follow-up hemoglobin values. The definitions of anemia used are similar to
those noted above for the analysis of anemia prevalence and associated factors.
Statistical Analysis
All statistical analyses were performed with SPSS software (version 10.0.5; SPSS,
Chicago, IL). Continuous variables with normal distribution were summarized using
mean and standard deviation (SD). For non-normal data, median and interquartile ratio
(IQR) were used. Frequencies and percentages were calculated for all the categorical
variables. Students t-test was used to compare the mean hemoglobins of the various CD4
cell count strata. Chi-squared for trend was used to determine significant trends in the
percent of patients with a given grade of anemia at different CD4 cell count strata using
Epi Info version 3.3.2, Centers for Disease Control and Prevention.
Univariate logistic regression was performed to understand the associations between age,
sex , HIV-associated co-morbidities, CD4 cell counts, and patterns of medication use for
non-anemic versus anemic patients. Bacterial pneumonia, bacterial meningitis, immune
reconstitution syndrome, idiopathic thrombocytopenia, hepatitis B virus infection, and
hepatitis C virus infection were not included in the univariate analysis due to small
17
frequency. A multivariate model was then built using forward stepwise techniques.
Variables that were statistically significant (p<0.05) were included in the multivariate
model. The best reduced model based on a 2 log likelihood value was built.
18
RESULTS
Analysis of Anemia Prevalence and Factors Associated with Anemia
Of the 8886 patients who had ever attended YRG CARE and were greater than 18 years
of age, 7069 had a hemoglobin value recorded in the database and were included in the
analysis. 1817 patients (20.4%) did not have a hemoglobin value and were excluded
from all analyses. Male-female ratio and mean age did not vary significantly between the
included and excluded groups: mean age was 32 in the included group vs. 31 in the
excluded group, while the included group was 69% male and the excluded group was
65% male. However, median time of follow up did vary between the two groups, with
the included group having a median of 332 days of follow up, while the excluded group
had a median of less than one day of follow-up.
The mean hemoglobin value for the cohort was 11.4 g/dL (SD: 2.4). Sixty percent of
patients in the cohort did not have anemia, while 19% had grade 1 anemia, 13% had
grade 2 anemia, 5% had grade 3 anemia, and 3% had grade 4 anemia. For the 209
patients on HAART in this cohort, the median time from HAART initiation to the date of
the hemoglobin value was 12 months (IQR: 4-24 months). For the 180 patients on
mono/dual therapy, the median time from therapy initiation to the date of the hemoglobin
value was 13 months (IQR: 5-32 months).
Of the 7069 patients with recorded hemoglobin values, 5638 patients (79.8%) had
associated CD4 cell count values. Patients with CD4 cell counts greater than 500 cell/L
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(n=1130) had a mean hemoglobin value of 12.5 g/dL (SD: 2.11); those between 351-500
cells/L (n=742) had a mean hemoglobin of 12.5 g/dL (SD: 2.23); those between 201-
350 cells/L (n=1208) had a mean hemoglobin of 11.9 g/dL (SD: 2.32); those between
101-200 cells/L (n=1058) had a mean hemoglobin of 11.1 g/dL (SD: 2.32); and those
between 0-100 cells/L (n=1500) had a mean hemoglobin of 10.2 g/dL (SD: 2.33). The
decline in mean hemoglobin values with decreased CD4 cell count strata was statistically
significant (p<0.001). The mean hemoglobin value for the 1431 individuals for whom a
CD4 cell count was not available was 11.1 g/dL (SD 2.43). The percent of individuals
without anemia declined from 78% at CD4 cell counts greater than 500 cells/L to 40%
at CD4 cell counts less than 100 cells/L (Figure 1). Each grade of anemia had a
corresponding statistically significant increasing trend with decreasing CD4 cell count
strata (Figure 1).
In the case-control comparison of non-anemic and anemic individuals, univariate analysis
showed that multiple factors were significantly associated with anemia (Table 1). The
following factors had the strongest association: being underweight (5.4 times increased
risk compared to overweight patients), having a CD4 cell count less than 100 cells/L
(5.3 times increased risk compared to those with a CD4 cell count greater than 500
cells/L), ascites, pulmonary TB, and extrapulmonary TB. Other HIV related co-
morbidities also had significant associations, including cytomegalovirus retinitis, oral
candidiasis, PCP, and cryptococcal meningitis. Lack of HAART use and lack of
cotrimoxazole use were both associated with a 1.4 times increased odds of anemia.
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In the multivariate model, CD4 cell count less than 100 cells/L and underweight BMI
had the strongest association with anemia, though the odds ratios were reduced from the
univariate results to 3.8 and 3.6 respectively (Table 1). In contrast, the odds ratio for
female gender increased from 1.6 to 3.3 times increased odds of anemia in comparison to
males. Pulmonary TB and extrapulmonary TB were both associated with an
approximately two times increased odds of anemia, while oral candidiasis had a milder
association with anemia. Lack of cotrimoxazole prophylaxis use was associated with a
1.5 times increased odds of anemia.
Analysis of the Impact of HAART on Anemia
After restricting the sample to those who had used HAART and had hemoglobin values
recorded, 401 patients had all the data necessary to analyze the impact of HAART on
anemia. In the control group, 77 patients the relevant hemoglobin values and a diagnosis
of clinical or immunological AIDS but never received HAART. The median baseline
CD4 counts were 163 and 218 cells/L for HAART and control groups respectively. The
mean times to follow-up hemoglobin were 7.0 and 7.1 months for the HAART and
control groups respectively. Among patients who initiated HAART, the numbers on d4T
vs. AZT-containing regimens were 308 and 93 patients respectively.
For patients who initiated HAART, the mean baseline hemoglobin of 10.7g/dL
significantly increased to 12.4g/dL during the year of follow-up (p<0.001, Figure 2 and
Table 2). While 46.6% of patients were not anemic at HAART initiation, this increased
significantly to 78.1% during follow-up (p<0.001). Grades 3 and 4 anemia decreased
21
from 12.5% to 2% for those on HAART (p<0.001, Table 2). By contrast, for the control
group of patients who never received HAART, the increase in mean baseline hemoglobin
from 10.50 to 11.10g/dL did not reach significance (p=0.06, Figure 2 and Table 3).
While the percent of non-anemic patients increased from 40.3 to 54.5% on follow-up in
this group, this was not significant (p=0.291, Table 3).
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DISCUSSION
This study highlights a high (40%) prevalence of anemia (using the WHO definition)
among HIV-infected individuals in South India. Using an alternative definition of
anemia (hemoglobin <12 g/dL for females and <13 g/dL for males), the prevalence of
anemia is 68%, which is similar to the 70-90% prevalence reported in other developing
countries.(6, 11, 15, 16) Most developing country studies have focused specifically on
groups at higher risk for anemia, such as pregnant or TB co-infected patients. Since this
study has patients of both genders distributed across all CD4 count strata, it may more
accurately reflect the prevalence of anemia in the general HIV-infected population.
Comparison of our data with the largest available population-based data on anemia in
South India (only available for women) makes clearer the increased risk of anemia in the
HIV-infected population (Table 4). When applying the same definition of anemia used in
population based surveys, approximately 70% of female patients at YRG CARE were
anemic, compared to 50% and 57% of women in surveys from Andhra Pradesh and
Tamil Nadu respectively,(2) the two Indian states from which our clinic derives its
patient population. Moreover, this higher prevalence of anemia exists despite female
patients at YRG CARE having a similar mean BMI and a lower percentage of
underweight individuals compared to the general population, suggesting this effect is due
to the impact of HIV disease rather than nutritional status alone.
The trend of increasing anemia with HIV disease progression shown in Figure 1 supports
data from prior studies.(3-5) Of note, the influence of HIV disease progression starts
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well before immunological AIDS, with a significant increase in the percent of patients
with anemia evident even at CD4 cell counts of 201-350 cells/L. It is important to
clarify that the trends in Figure 1 do not imply that anemia increases in HIV-infected
patients solely due to a decline in CD4 cell count. Rather, the trend of increasing anemia
with immunosuppression likely has multiple causes, including an increased burden of
opportunistic infections, higher HIV viral load, and malnutrition resulting from AIDS.
The multivariate analysis helps sort out the independent contribution of these various
factors to anemia. Similar to findings in other studies,(4, 7, 13) a low CD4 cell count had
a strong independent association with anemia even after controlling for major
opportunistic infections and malnutrition. Unlike previous studies, however, our data
shows that this increased risk happens even at CD4 cell counts greater than 200 cells/L.
This independent association between progressive immunosuppression and increasing
anemia may be explained by increasing HIV viral loads that cause immunosuppression.
While the exact pathophysiology of anemia due to the HIV virus itself is unclear, most
studies suggest that the virus inhibits hematopoiesis either directly through infection of
progenitor cells or indirectly through upregulation of cytokines.(11) Unfortunately, the
prohibitive cost of viral load testing in the setting of this study precludes a direct analysis
of this hypothesis. Part of the association between CD4 cell count and anemia in this
study may also be due to the fact that anemia has been shown to independently accelerate
immunological disease progression.(6) Alternatively, low CD4 cell count could be a
surrogate marker for some other aspect of disease progression not captured in this
analysis.
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While the association of anemia with underweight BMI is not surprising, it is of specific
relevance to the Indian setting, where the rate of chronic malnutrition is among the
highest in the world, with a prevalence of childhood under-nutrition nearly double that in
sub-Saharan Africa.(27) Of note, even individuals with a BMI in the normal range had
twice the odds of anemia as compared to those with overweight BMIs. Low BMI is
associated with deficiencies of many nutrients—including iron, folate, B12, and vitamin
A—that contribute directly to anemia. The association between low BMI and anemia
may also reflect widespread intestinal helminth infection, which can cause chronic blood
loss and worsen micronutrient deficiencies. In addition, for particular segments of the
population (e.g. upper castes with dietary restrictions), a strict vegetarian diet may
exacerbate these nutrient deficiencies. The 1.3 times adjusted odds of anemia with oral
candida infection may also reflect micronutrient deficiency as candidiasis, especially with
esophageal involvement, can decrease oral intake.
Women had a 3.3 times adjusted odds of being anemic compared to men. This most
likely reflects the high rate of baseline iron deficiency anemia in Indian women due to
menstrual blood loss in the context of poor nutritional status;(2) moreover, malnutrition
in India disproportionately affects females.(27) In addition, prior studies have found
multiparity to be the most significant risk factor for anemia in women. Lack of
cotrimoxazole prophylaxis use was associated with a 1.5 times adjusted odds of anemia, a
finding previously noted in other studies.(4) While this association may seem
counterintuitive, since anemia is occasionally an adverse effect of cotrimoxazole, it may
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be explained by the protective effect of cotrimoxazole prophylaxis against multiple
opportunistic infections which may cause anemia.
An important finding in this analysis not previously highlighted in U.S. and European
studies is the two times increased odds of anemia in patients with pulmonary and
extrapulmonary TB, even after adjusting for CD4 cell count and malnutrition. TB is the
second most common opportunistic infection in South India after oral candidiasis (18, 28)
and therefore may substantially increase the burden of anemia among HIV-infected
patients in South India. Table 5 shows that the high 81% prevalence of anemia among
patients with pulmonary TB in this cohort (as compared to the lower 68% prevalence
using the same criteria for the overall cohort) is comparable to the prevalence found in
other studies of HIV/TB co-infected patients from Malawi and Uganda.(15, 16) The
etiology of anemia in TB is likely multifactorial, deriving partially from anemia of
chronic disease (associated with increased IL-6) and partly from deficiencies of nutrients
such as iron, vitamin A, and selenium.(15) Also, in some cases, severe anemia may be
the only clue to diagnosing occult tuberculous infection of the bone marrow.(19)
It is important to highlight the way the synergistic cycle of immunosuppression,
malnutrition, and TB may impact rates of anemia. High HIV viral burden and TB both
cause a net catabolic state, which can lead to severe wasting.(29) Malnutrition and HIV
immunosuppression are two of the strongest risk factors for TB infection.(30) TB and
malnutrition have both been shown to independently accelerate immunological disease
progression in HIV-infected patients.(31, 32) The net result is a downward spiral placing
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HIV-infected patients in TB-endemic countries at very high risk for developing anemia.
Anemia, in turn, independently accelerates the rate of immunological disease progression
and decreases survival time for people living with HIV.(4, 6) Therefore, in addition to
roll-out of HAART, nutritional support and aggressive diagnosis and treatment of
tuberculosis should be the cornerstones of anemia management for HIV-infected
individuals in India.
While Western studies have showed decreased anemia with HAART use,(14, 21, 22) to
our knowledge, the study described here is the first from a developing country to examine
this issue. Despite multiple co-morbidities in our patient population, our analysis
suggests that the beneficial effects of HAART induced immune reconstitution on anemia
are similar or even superior to those found in Western studies. Anemia resolved in nearly
60% of patients in this sample within the first year of HAART use. While there was also a
mild increase in mean hemoglobin in the control group, this change did not reach
statistical significance, and the magnitude of the change was much smaller than that in
the group on HAART. This increase in mean hemoglobin in the control group may be
explained by the fact that many of these patients were probably treated for opportunistic
infections (especially TB), given nutritional supplementation, and started on
cotrimoxazole prophylaxis prior to their follow-up hemoglobin tests. The much greater
increase in mean hemoglobin in the group on HAART suggests that antiretroviral therapy
adds significant benefit beyond that provided by basic clinical care without HAART, by
essentially reversing the trend of increasing anemia with progressive immunosuppression
(Figure 1).
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The main limitation of the analysis of factors associated with anemia is its cross-sectional
design, which precludes definite determination of the temporal and causal relationships
between anemia and significantly associated factors. Also, the YRG CARE observation
database does not capture data on laboratory findings that could better characterize the
causes of anemia (i.e., mean corpuscular volume, iron studies, reticulocyte count).
Therefore, it is not possible to clarify the frequency of clinically diagnosed iron
deficiency, B12 deficiency, folate deficiency, or anemia of chronic disease in this
population. Certain medications commonly used in this population—most importantly
anti-tuberculosis therapy, but also fluconazole and ganciclovir—also could not be
included the analysis because they are not captured in the database.
Many HIV-associated co-morbidities, such as PCP, cryptococcal meningitis,
cytomegalovirus retinitis, oral hairy leukoplakia, lymphadenopathy, and ascites did not
have statistical power to be included in the multivariate model, despite significant
univariate associations. While more data would be needed to calculate their independent
odds ratios, it is possible that much of the association between anemia and these factors
in univariate analysis is actually due to low CD4 cell counts. For instance, 92% of PCP
episodes included in this analysis, 95% of cryptococcal meningitis episodes, 97% of
cytomegalovirus episodes, 83% of oral hairy leukoplakia episodes, and 93% of ascites
episodes occurred at CD4 counts less than 350 cells/L. In contrast, lymphadenopathy
episodes were more widely distributed over all CD4 strata, with only 73% of cases
occurring at CD4 cell counts below 350 cells/L and 49% below 200 cells/L.
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Approximately 20% of the 8886 adult patients who had ever attended YRG CARE did
not have hemoglobin values recorded in the database, which may introduce some
selection bias into the study with possible over- or underestimation of the prevalence of
anemia in this cohort. Many of these patients likely had absent hemoglobin values
because they only visited the clinic once (as indicated by the median follow-up time of
less than one day for the group) and did not return for a follow-up visit. Since YRG
CARE was once the only major HIV treatment center in South India, patients frequently
traveled from as far away as northern Andhra Pradesh to access care at the clinic.
However, due to distance, many of these patients could not afford or were not willing to
return after the initial HIV diagnosis for a follow-up visit, which is normally when
baseline labs are collected. While there is no reason to believe that these patients would
have had lower or higher hemoglobin values compared to the rest of the cohort (due to
the similarity in demographics), we can only speculate on this point.
The analysis of the impact of HAART on anemia also has limitations. Most significantly,
despite the fact that nearly 1,600 patients at YRG CARE had been started on HAART at
the time this study was done, only 401 patients could be included in the analysis. This is
because only 659 of the 1,600 patients on HAART had baseline hemoglobins, only 551
of these 659 patients had continued HAART for three months without significant
treatment interruption, and only 401 of these 551 patients had follow-up hemoglobin
values.
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We do not believe that the exclusion of these patients significantly biases our study.
Patients excluded due to inadequate length of HAART treatment or significant treatment
interruption are not relevant to this analysis, since they would not allow us to adequately
assess the impact of sustained HAART use on anemia. Patients excluded due to absence
of baseline hemoglobin values likely represent individuals who either had a prior
hemoglobin recorded more than three months prior to HAART initiation or who started
on HAART before baseline hemoglobin testing became the standard-of-care at the clinic.
Although this is a weakness of the analysis, we have no reason to believe that the




This study has important implication for both public health policy and the clinical
management of people living with HIV/AIDS in India. Most importantly, the dramatic
resolution of anemia in a large proportion of patients following HAART initiation
highlights yet another way that this therapy benefits the lives of people living with HIV
in developing countries. Only a few years ago, many Western public health experts
doubted that distribution of HAART could be successfully implemented in the Indian
context.(33) Our data contribute to a growing body of literature underscoring the positive
effects of HAART roll-out in resource-limited settings, which include remarkable
decreases in mortality,(34, 35) as well as in the incidence of TB and other opportunistic
infections.(34, 36, 37) By reducing symptoms of fatigue and exhaustion, the resolution
of anemia in many patients on HAART may drastically improve quality of life (8, 9) and
increase survival time (4). In addition, it may facilitate the livelihood of people living
with HIV in settings where many rely on physical labor for survival and do not have
access to disability insurance. Indeed, our data should reinforce the determination for
increased roll-out of HAART in developing countries, especially when this life-saving
therapy still remains unavailable to the majority of those in need.(38)
This study also highlights the striking impact of undernourishment on anemia in this
population, in which the synergy of tuberculosis, increased catabolism from HIV, chronic
diarrhea, and esophageal candidiasis results in profound wasting. In addition to targeted
nutritional supplementation (i.e., iron and B12 supplementation), programs that ensure
food security for this vulnerable population may be critical to reducing the burden of
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anemia. For example, one of the largest antiretroviral roll-out programs in Haiti provides
its most undernourished patients with a monthly supply of beans, rice, and vegetable
oil.(35) Tuberculosis also emerges as a major factor contributing to anemia, which
emphasizes the importance of tuberculosis control in this population. Indeed, roll-out of
HAART, nutritional support, and aggressive diagnosis and treatment of tuberculosis
should be the cornerstones of anemia management for HIV-infected individuals in India.
Not only are HIV-positive women three times more likely to be anemic than HIV-
positive men, but they also have significantly increased risk compared to women in the
general Indian population (Table 4). HIV clinicians should monitor for anemia from the
moment women enroll into care, and they should be aggressive in ensuring nutritional
supplementation.
The high (45-60%) prevalence of anemia in patients with CD4 cell counts less than 200
cells/L has implications for the choice of initial HAART regimen in developing
countries. Since myelosuppression is one of the adverse effects of zidovudine (AZT), use
of this drug is contraindicated in patients with hemoglobins less than 11 g/dL, especially
since pre-existing anemia is a risk factor for this adverse effect.(39, 40) Therefore, more
than half of the patients with immunological AIDS in this cohort would not be eligible
for initiation on an AZT-based HAART regimen. However, stavudine (d4T)—the only
other affordable nucleoside reverse transcriptase inhibitor (NRTI) option in most
resource-limited settings—may not be tolerated by many patients due to its frequent
mitochondrial toxicity, which causes complications such as peripheral neuropathy,
lipoatrophy, hypercholesterolemia, hyperglycemia, lactic acidosis, and pancreatitis.(41)
32
One approach for minimizing the toxicities of these two drugs would be to initiate
patients on a d4T-containing regimen and then substitute AZT for d4T 6-12 months after
initiation. Since our data shows that HAART use contributes to resolution of anemia in
approximately 60% of patients within one year of therapy initiation, a majority of patients
started on d4T-containing HAART would eventually become non-anemic and qualify for
AZT substitution. AZT substitution would then prevent the long-term toxicities of d4T.
While most patients started on d4T-containing regimens could benefit from AZT-
substitution, a significant subset of patients may have persisting anemia despite long-term
HAART use. When such patients experience toxicity severe enough to require d4T
discontinuation, they are often left without any affordable NRTI option for their HAART
regimens. This highlights the urgent need to make NRTIs with different toxicity profiles,
such as tenofovir and abacavir, more accessible in resource-limited settings.
Our data also suggest that earlier initiation of HAART may help reduce the incidence of
anemia and minimize toxicities from d4T and AZT. Current WHO guidelines
recommend initiating HAART in relatively asymptomatic (WHO stages I and II) patients
only at CD4 counts <200 cells/L.(25) However, our data show that the risk of anemia
in HIV-infected patients begins to increase even at CD4 counts <350 cells/L, with the
majority of patients being anemic at CD4 counts <200 cells/L (as compared to only
22% at CD4 counts >350 cells/L). Therefore, early initiation of HAART in
asymptomatic patients with CD4 counts >350 cells/L may help prevent the development
of anemia in a significant proportion of patients. Early HAART initiation would also
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mean that a larger proportion of patients would qualify for an AZT-containing regimen
(since a larger proportion would be non-anemic), which would help minimize usage of
the relatively more toxic drug d4T. It may also greatly decrease the burden of
tuberculosis in this population, since a large proportion of HIV-infected individuals in
TB-endemic settings experience episodes of active tuberculosis even at CD4 counts
between 200-350 cells/L.(42) While earlier therapy initiation may increase the overall
cost of HAART use in developing countries, by preventing the development of anemia,
this approach may actually bring significant economic benefits by allowing people living
with HIV to lead more active and productive lives.(8-10)
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Male 3136 (74) 1771 (63) 1.0 1.0
Female 1129 (26) 1030 (37) 1.6 (1.5-1.8) 3.3 (2.9-3.7)
Age
18-30 1842 (43) 1101 (39) 1.0 1.0
31-50 2261 (53) 1572 (56) 1.2 (1.05-1.3) 1.1 (1.01-1.3)
>50 163 (4) 130 (5) 1.3 (1.04-1.7) 1.6 (1.2-2.04)
Body Mass Index
Overweight (>25) 373 (9) 67 (2) 1.0 1.0
Normal (18.5-24.9) 1499 (35) 641 (23) 2.4 (1.8-3.1) 1.9 (1.5-2.6)
Underweight (<18.5) 897 (21) 872 (31) 5.4 (4.1-7.1) 3.6 (2.6-4.8)
Not available 1497 (35) 1223 (44) --
CD4 cell count (cells/L)
>500 882 (21) 248 (9) 1.0 1.0
351-500 578 (13) 164 (6) 1.0 (0.8-1.3) 0.94 (0.7-1.2)
201-350 833 (19) 375 (13) 1.6 (1.3-1.9) 1.4 (1.2-1.8)
101-200 579 (14) 479 (17) 2.9 (2.4-3.5) 2.2 (1.8-2.7)
0-100 599 (14) 901 (32) 5.3 (4.5-6.4) 3.8 (3.1-4.6)
Not available 795 (19) 636 (23) --
ART use
On HAART 140 (3) 69 (3) 1.0
On Mono or dual therapy 112 (3) 68 (2) 1.2 (0.8-1.8)
Not on ART 4014 (94) 2666 (95) 1.4 (1.01-1.8)
Use of Cotrimoxazole
Prophylaxis
Yes 273 (6) 134 (5) 1.0 1.0
No 3993 (94) 2669 (95) 1.4 (1.1-1.7) 1.5 (1.2-2.0)
Pulmonary tuberculosis
No 2690 (63) 1155 (41) 1.0 1.0
Yes 1576 (37) 1648 (59) 2.5 (2.2-2.7) 1.9 (1.6-2.1)
Extrapulmonary TB
No 3898 (91) 2261 (81) 1.0 1.0
Yes 368 (9) 542 (19) 2.5 (2.2-2.9) 2.1 (1.8-2.4)
Oral Candidiasis
No 2642 (62) 1219 (43) 1.0 1.0
Yes 1624 (38) 1584 (57) 2.1 (1.9-2.3) 1.3 (1.1-1.4)
Esophageal Candidiasis
No 4179 (98) 2700 (96) 1.0
Yes 87 (2) 103 (4) 1.8 (1.4-2.4)
PCP
No 4063 (95) 2539 (91) 1.0
Yes 203 (5) 264 (9) 2.1 (1.7-2.5)
Cryptococcal meningitis
No 4188 (98) 2704 (96) 1.0
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Yes 78 (2) 99 (4) 2.0 (1.5-2.6)
CMV
No 4228 (99) 2745 (98) 1.0
Yes 38 (1) 58 (2) 2.4 (1.6-3.6)
Oral hairy leukoplakia
No 4063 (95) 2639 (94) 1.0
Yes 203 (5) 164 (6) 1.2 (1.01-1.5)
Lymphadenopathy
No 3693 (87) 2264 (81) 1.0
Yes 573 (13) 539 (19) 1.5 (1.3-1.7)
Herpes zoster
No 3561 (84) 2355 (84) 1.0
Yes 705 (16) 448 (16) 0.96 (0.84-1.1)
Herpes simplex
No 3774 (89) 2452 (88) 1.0
Yes 492 (11) 351 (12) 1.1 (0.9-1.3)
Gastroenteropathy
No 3807 (89) 2405 (86) 1.0 1.0
Yes 459 (11) 398 (14) 1.4 (1.2-1.6) 1.1 (0.4-1.3)
Bacterial infections of the skin
No 4206 (99) 2767 (99) 1.0
Yes 60 (1) 36 (1) 0.9 (0.6-1.4)
Ascites
No 4256 (100) 2780 (99) 1.0
Yes 10 (0) 23 (1) 3.5 (1.7-7.4)
Renal Disease
No 4148 (97) 2717 (97) 1.0
Yes 118 (3) 86 (3) 1.1 (0.7-1.2)
Syphilis
No 2504 (59) 1559 (56) 1.0
Yes 184 (4) 125 (4) 1.1 (0.9-1.4)
Not tested 1578 (37) 1119 (40) --
Malaria
No 4240 (99) 2780 (99) 1.0
Yes 24 (1) 23 (1) 1.5 (0.8-2.6)
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Table 2: Impact of at least three months of HAART use on the severity of anemia
and hemoglobin values during the first year after HAART initiation (n=401)
At HAART initiation
(number of patients (%))
At time of follow-up
(number of patients (%))
p-value
No anemia 187 (46.6) 313 (78.1)
Grade 1 92 (22.9) 59 (14.7)
Grade 2 72 (18.0) 21 (5.2)
Grade 3 30 (7.5) 6 (1.5)
Grade 4 20 (5.0) 2 (0.5) <0.001
Mean Hemoglobin (g/dL) 10.65 12.35 <0.001
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Table 3: Change in severity of anemia and hemoglobin values during the first year
for patients who qualified for HAART (i.e. clinical or immunological AIDS) but
never initiated therapy (n=77)
At time of AIDS
diagnosis
(number (%))
At time of follow-up
(number (%))
p-value
Grade 0 31 (40.3) 42 (54.5)
Grade 1 23 (29.9) 14 (18.2)
Grade 2 16 (20.8) 11 (14.3)
Grade 3 6 (7.8) 10 (13.0)





Table 4: Prevalence of anemia among women at YRG CARE versus women in the









Any anemia (%) 70.4 56.5 49.8
Mild (%) 41.5 36.7 32.5
Moderate (%) 25.4 15.9 14.9




BMI <18.5 (%) 24.5 29.0 37.4
*Based on the following definitions: “Any anemia” is any hemoglobin value <12 g/dL, “mild anemia” is
any hemoglobin value between 10.0-11.9 g/dL, “moderate anemia” is any hemoglobin value between 7.0-
9.9 g/dL, and “severe anemia” is any hemoglobin value <7 g/dL.
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Table 5: Prevalence of Anemia in HIV and Pulmonary TB Co-infected Patients in
Various Studies from Developing Countries
Study
Location


















3224/0 81% --- 18.8
Malawi(15) 370/130 88% 77% 18.4
Uganda(16) 261/278 71% 50% 18.5
*All three prevalences of anemia above use a definition of anemia as any hemoglobin <12 g/dL in women
and <13 g/dL in men
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Illustration 1
Front of YRG CARE clinic at night.
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Illustration 3
The staff of YRG CARE with actor Richard Gere.
